News

In an interview with Targeted Oncology, Lucy Gilbert, MD, MSc, discussed the interim findings for mirvetuximab in combination with bevacizumab as treatment of patients with platinum-agnostic ovarian cancer.

In an interview with Targeted Oncology, Andrew L. Coveler, MD, discussed the phase 1 trial study of SEA-CD40 combined with a chemotherapy regimen, which he recently presented during the ASCO Virtual Scientific Program.

The FDA expanded the approval of gemtuzumab ozogamicin to include an indication for the treatment of newly diagnosed pediatric patients with CD33-positive acute myeloid leukemia, which includes patients as young as 1 month old.

"We can potentially offer a new treatment option for patients with high-risk HR-positive, HER2-negative early breast cancer. "

“These results, complimented with a favorable safety profile, indicate the utility of this novel immunological combination as a potential treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma."

A pooled analysis of phase 3 clinical trials in advanced renal cell carcinoma showed that combination immunotherapy can reduce toxicity compared with sunitinib.

“These interim results from the PROTECTIVE-2 Phase 3 study, which compares the Plinabulin-Neulasta combination to Neulasta alone, have the potential to be clinically meaningful for cancer patients receiving chemotherapy."

“Today’s approval for the prevention of HPV-related oropharyngeal and other head and neck cancers represents an important step in Merck’s mission to help reduce the number of men and women affected by certain HPV-related cancers.”

"Breakthrough designation for the companion diagnostic is a big step forward in our endeavor to ensure that more clinicians can have quicker access to comprehensive genomic information."

"This interim analysis demonstrated ropeginterferon in low-risk patients is more efficacious in keeping the hematocrit [at target levels]. In addition, we get a better quality of life and the target was reached with a reduction of phlebotomy needs."

"The data from this ongoing trial of eprenetapopt with azacitidine continue to be very encouraging in these most difficult-to-treat [patients with] TP53-mutant MDS and AML, who not only have at least one TP53 mutation but the majority of whom also have high risk cytogenetic abnormalities,."

"Treatment with liso-cel resulted in high response rates and durable complete responses in a patient population considered to be high risk.”

In an interview with Targeted Oncology following the American Urological Association Virtual Annual Meeting, Eric A. Klein, MD, discussed the importance of molecular testing in Caucasian and African American patients with newly diagnosed prostate cancer. He also discussed the pros and cons of active surveillance.

We believe that lenvatinib could be a standard second-line treatment option for patients with thymic carcinoma.”

"We believe DKN-01 has the potential to be an important new therapy for this patient population that remains an area of high unmet medical need."

Targeted Oncology reviews trending news online for the week of June 12, 2020, including recent news from the FDA, updates in oncology, and new information regarding COVID-19.

The study showed that the development of immune-related adverse events in advanced solid tumors was positively correlated with improved progression-free survival and overall survival in a retrospective analysis, which also showed that Caucasian patients developed immune-related adverse events more frequently than African American patients.

Glioblastoma currently has a dismal survival rate of only 14.6 months from its diagnosis. We believe berubicin, which based on limited clinical data appears to be the first anthracycline to cross over the blood-brain barrier in adults, provides a potentially novel therapy for the treatment of malignant gliomas.

“Larotrectinib is extremely well-tolerated, and when we look at the poster from ASCO, we can actually see there are very few grade 3 toxicities that are attributed to larotrectinib. With a 10% complete response rate and all the patients getting really deep responses, it just blows almost all of the comparative chemotherapies in each of these cancers out of the park."

“The completion of target patient enrollment in the Phase 3 ATHENA trial is an important milestone for Clovis and a critical step toward developing additional therapeutic options for women with advanced ovarian cancer."

In an interview with Targeted Oncology, Raajit K. Rampal, MD, PhD, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discussed the novel agent, APR-246, and its significance for use in the patients with myelodysplastic syndrome and acute myeloid leukemia

In an interview with Targeted Oncology, Jeff P. Sharman, MD, discussed the findings for the combination of ublituximab plus ibrutinib as treatment of patients with high-risk relapsed/refractory chronic lymphocytic leukemia.

The FDA granted approval to pegfilgrastim-apgf, a biosimilar of pegfilgrastim, which is indicated to decrease the incidence of infection due to febrile neutropenia in patients with non-myeloid malignancies who are receiving myelosuppressive anti-cancer agents associated with a clinically significant incidence of febrile neutropenia.

The FDA granted approval to nivolumab for the treatment of patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma after receiving prior fluoropyrimidine- and platinum-based chemotherapy.

In an interview with Targeted Oncology, Marcia Brose, MD, PhD, discussed the role of genetic testing in patients with thyroid cancer and the current treatment landscape.

In an interview with Targeted Oncology, David G. Maloney, MD, PhD, discussed findings from administration of chimeric antigen receptor T-cell therapy in the outpatient setting for patients with B-cell lymphomas.

"This approach provides potential benefits for both clinicians and patients: clinicians may gain greater control over cancer care, and patients may experience better clinical outcomes and an improved quality of life."

“While the sample size and power are limited, these results suggest that a higher HER2 FISH ratio at baseline core biopsy may be a potential biomarker to select patients for neoadjuvant dual anti-HER2 therapy without chemotherapy."

"While we are disappointed in these study results, Keytruda has been established as an important option in the treatment of metastatic bladder cancer, and we are committed to continuing our research to help more patients with this disease."

In an interview with Targeted Oncology, Scott Tykodi, MD, PhD, discussed findings from the analysis from the KEYNOTE-427 trial in patients with clear cell renal cell carcinoma.